| Autor: |
Smith, Robert A, Raugi, Dana N, Nixon, Robert S, Seydi, Moussa, Margot, Nicolas A, Callebaut, Christian, Gottlieb, Geoffrey S, Group, for the University of Washington–Senegal HIV-2 Study |
| Předmět: |
|
| Zdroj: |
Journal of Infectious Diseases; 5/15/2024, Vol. 229 Issue 5, p1290-1294, 5p |
| Abstrakt: |
The activity of lenacapavir against human immunodeficiency virus type 1 (HIV-1) has been extensively evaluated in vitro, but comparable data for human immunodeficiency virus type 2 (HIV-2) are scarce. We determined the anti–HIV-2 activity of lenacapavir using single-cycle infections of MAGIC-5A cells and multicycle infections of a T-cell line. Lenacapavir exhibited low-nanomolar activity against HIV-2, but was 11- to 14-fold less potent against HIV-2 in comparison to HIV-1. Mutations in HIV-2 that confer resistance to other antiretrovirals did not confer cross-resistance to lenacapavir. Although lenacapavir-containing regimens might be considered for appropriate patients with HIV-2, more frequent viral load and/or CD4 testing may be needed to assess clinical response. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
